Skip to main content

belcesiran

Generic: DCR-A1AT·Code: DCR-A1AT

belcesiran: developed by 1 company · 1 clinical trial tracked.

belcesiran evidence translation

What we can confirm

What it means

Source-backed records connect belcesiran to DRNA; that link alone does not prove the drug works.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

How could belcesiran → DRNA affect its developer, and what evidence supports the link?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence1 indications · 0 study sponsors

Study sponsors

No additional listed-company sponsor is linked.

Development Pipeline (1)
Clinical Trials (1)

A Phase 2, Randomized, Double-blind, Placebo-Controlled Study Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Two Dose Levels of Belcesiran in Patients With Alpha-1 Antitrypsin Deficiency-Associated Liver Disease

NCT04764448·Phase 2·DRNA
Terminated

Primary endpoint: Number of Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

InterventionalRandomizedtriple16 targetStarted 2021-02Completion 2024-0523 sites · Australia, Austria, Belgium, Canada…Dicerna Pharmaceuticals, Inc., a Novo Nordisk company

Frequently asked questions

Who is developing belcesiran?

belcesiran is being developed by Dicerna Pharmaceuticals Inc.

How many clinical trials involve belcesiran?

BioSniper tracks 1 clinical trial involving belcesiran.